2.26% of the stock is owned by corporate insiders. Several equities research analysts recently commented on MNMD shares. HC ...

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $27.71. MNMD has been the subject of a number of research analyst reports.

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23.

Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Check the time stamp on this data. Updated AI-Generated Signals for Mind Medicine (mindmed) Inc. (MNMD) available here: MNMD.

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The firm decreased its portfolio allocation in MNMD by 19.12% over the last quarter ... Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved ...